Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pathogenesis and therapeutic targets in spinal muscular atrophy (SMA)
S. Lefebvre, Catherine Sarret
Archives de Pédiatrie (2020) Vol. 27, Iss. 7, pp. 7S3-7S8
Open Access | Times Cited: 16

Showing 16 citing articles:

Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy
Tejal Aslesh, Toshifumi Yokota
Cells (2022) Vol. 11, Iss. 3, pp. 417-417
Open Access | Times Cited: 49
Emerging Gene Therapy Approaches in the Management of Spinal Muscular Atrophy (SMA): An Overview of Clinical Trials and Patent Landscape
Aleksei S. Ponomarev, Daria S. Chulpanova, Lina M. Yanygina, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13743-13743
Open Access | Times Cited: 16
Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma®) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System
Rosanna Ruggiero, Nunzia Balzano, Maria Maddalena Nicoletti, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 394-394
Open Access | Times Cited: 6
Comparison of neurofilament light and heavy chain in spinal muscular atrophy and amyotrophic lateral sclerosis: A pilot study
Jinyue Li, Yi Dai, Xiaohan Sun, et al.
Brain and Behavior (2023) Vol. 13, Iss. 5
Open Access | Times Cited: 11
Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges
Umme Sabrina Haque, Toshifumi Yokota
Genes (2024) Vol. 15, Iss. 8, pp. 999-999
Open Access | Times Cited: 4
An Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy
Yueyi Li, Hongyu Zeng, Yuhao Wei, et al.
Human Gene Therapy (2023) Vol. 34, Iss. 5-6, pp. 180-191
Closed Access | Times Cited: 10
Chimeric Cell Therapies as a Novel Approach for Duchenne Muscular Dystrophy (DMD) and Muscle Regeneration
Katarzyna Budzynska, Maria Siemionow, Katarzyna Stawarz, et al.
Biomolecules (2024) Vol. 14, Iss. 5, pp. 575-575
Open Access | Times Cited: 3
Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges
Umme Sabrina Haque, Toshifumi Yokota
(2024)
Open Access | Times Cited: 3
Neurophysiological Evaluation of Autonomic Dysfunction in Spinal Muscular Atrophy: A Case-Control Study
Μarianna Papadopoulou, Christina Zompola, Georgia Papagiannopoulou, et al.
Acta Neurologica Scandinavica (2024) Vol. 2024, Iss. 1
Open Access | Times Cited: 2
Total tau in cerebrospinal fluid detects treatment responders among spinal muscular atrophy types 1–3 patients treated with nusinersen
Goran Šimić, Vana Vukić, Marija Babić, et al.
CNS Neuroscience & Therapeutics (2022) Vol. 30, Iss. 3
Open Access | Times Cited: 11
Clinical Pharmacology in Drug Development for Rare Diseases in Neurology: Contributions and Opportunities
Bilal Abuasal, Mariam A. Ahmed, Priyank Patel, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 111, Iss. 4, pp. 786-798
Closed Access | Times Cited: 12
Ultrastructural characterization of peripheral denervation in a mouse model of Type III spinal muscular atrophy
Federica Fulceri, Francesca Biagioni, Fiona Limanaqi, et al.
Journal of Neural Transmission (2021) Vol. 128, Iss. 6, pp. 771-791
Open Access | Times Cited: 4
Bridging the Gap With Clinical Pharmacology in Innovative Rare Disease Treatment Modalities: Targeting DNA to RNA to Protein
Lucy Lee, Rakesh Gollen, Anas M. Fathallah, et al.
The Journal of Clinical Pharmacology (2022) Vol. 62, Iss. S2
Closed Access | Times Cited: 3
Spinal Muscular Atrophy Treatment: The MTOR Regulatory Intervention
Naser‐Aldin Lashgari, Nazanin Momeni Roudsari, Maryam Shayan, et al.
Current Medicinal Chemistry (2023) Vol. 31, Iss. 12, pp. 1512-1522
Closed Access | Times Cited: 1
Efficacy of Nusinersen Treatment in Type 1, 2, and 3 Spinal Muscular Atrophy: Real-World Data from a Single-Center Study
Anna Lemska, Piotr Ruminski, Jakub Szymarek, et al.
Neurology International (2024) Vol. 16, Iss. 6, pp. 1266-1278
Open Access
General principles of vaccination of patients with neuromuscular diseases
M. S. Skorikov, D. Vlodavets
Neuromuscular Diseases (2023) Vol. 13, Iss. 3, pp. 40-47
Open Access
Page 1

Scroll to top